部门首页部门概况学科建设科学研究技术开发国际合作资料下载
部门首页
 重要通知 
 学术活动 
相关文章
读取内容中,请等待...
 
学术活动
您的位置: 部门首页>学术活动>正文

【学术报告】题目:Development of basic tools for glycoscience and their application to translational research

时间:[2018-04-25]  来源:生命与医药学院、科研与学科工作部  点击量:

题目:Development of basic tools for glycoscience and their application to translational research' 

报告人:成松久教授

报告时间:2018426 1330

报告地点:F03-201

报告人简介:Dr. Narimatsu is founder and Director of the Research Center of Medical Glycoscience (RCMG), a part of National Institute of Advanced Industrial Science and Technology (AIST) in Japan. He graduated from the School of Medicine and Graduate School of Medicine at Keio University where he received his MD and PhD respectively. During his postdoctoral studies at U.S. National Institutes of Health (NIH), he successfully cloned the first glycosyltransferase, beta1,4galactosyltransferase and thereafter, has continuously devoted his scientific career to finding and cloning many new glycosyltransferases. In 2000 he joined AIST and has since lead 3 national projects to facilitate the progress of glycoscience: the Glycogene Project, the Structural Glycomics Project, and the Medical Glycomics Project.

 

报告摘要:We have been developing many basic technologies which are required for glycoscience for these 17 years.  Firstly, we discovered many glycogenes which are responsible for glycerin synthesis. We can now synthesize a variety of glycan structures using such recombinant enzymes. For structural analysis of glycans, we have mainly developed two technologies, 1) MS based analysis of glycans and glycopeptides, and 2) lectin microarray that is the most sensitive array for glycan profiling.  These many technologies were applied to the medical issues,  particularly, to develop diagnostics.  We have been successful in completing the assay kit for the diagnosis of liver fibrosis. This diagnosis kit named M2BPGi is now world-widely used for the diagnosis of chronic hepatitis and liver cirrhosis. The validation studies on M2BPGi verified its clinical importance for the level of liver fibrosis, and over 50 scientific clinical papers describing M2BPGi were already reported to date. The second success named MUC1Gi is the diagnostics for cholangiocarcinoma. Thus, we are now developing clinically useful diagnostics for several diseases.


上一条:【学术报告】环境纳米颗粒在细胞/微生物中的界面毒理学研究

下一条:【学术报告】Symposium on Sustainable Chemistry and Engineering

关闭窗口

版权所有:大连理工大学 地址:中国 • 辽宁省大连市甘井子区凌工路2号 邮编:116024
大连理工大学盘锦校区 地址:中国 • 辽宁省盘锦市辽东湾新区大工路2号 邮编:124221
辽ICP备05001357号 电话:0427-2631965